Pharmacological inhibition of LRRK2 cellular phosphorylation sites provides insight into LRRK2 biology

Mutations in LRRK2 (leucine-rich repeat kinase 2) have been linked to inherited forms of PD (Parkinson's disease). Substantial pre-clinical research and drug discovery efforts have focused on LRRK2 with the hope that small-molecule inhibitors of the enzyme may be valuable for the treatment or p...

Full description

Bibliographic Details

Published in:	Biochemical Society transactions Vol. 40; no. 5; p. 1158
Main Authors:	Zhao, Jing, Hermanson, Spencer B, Carlson, Coby B, Riddle, Steven M, Vogel, Kurt W, Bi, Kun, Nichols, R Jeremy
Format:	Journal Article
Language:	English
Published:	England 01-10-2012
Subjects:	Binding Sites - drug effects Humans Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Phosphorylation - drug effects Protein Kinase Inhibitors - pharmacology Protein-Serine-Threonine Kinases - antagonists & inhibitors Protein-Serine-Threonine Kinases - genetics Protein-Serine-Threonine Kinases - metabolism Structure-Activity Relationship
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!